Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Who We Are
    • IP Portfolio
    • Management Team
    • Board of Directors
    • Careers
  • Technology
  • Pipeline
    • Kappa Opioid Receptor Agonist
    • Nalmefene Implant
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Publications
    • Posters
    • Media Resources
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Company Information
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Titan FCOI Policy
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact
  • Search

Press Releases

  • Home
  • News
  • Press Releases
News

Navigate News

  • Overview
  • Press Releases
  • Events
  • Presentations
  • In the News
  • Publications
  • Posters
  • Media Resources

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2016 Financial Results

November 3, 2016

Probuphine® Implant for Opioid Dependence Featured at 2016 International Society of Addiction Medicine Meeting

October 28, 2016

Popular Science Recognizes Probuphine as One of the 2016 "Best of What's New"

October 20, 2016

Titan Pharmaceuticals Reports Second Quarter 2016 Financial Results

August 9, 2016

Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2016 Financial Results

August 3, 2016

Titan Pharmaceuticals Added to Russell 3000 Index

June 27, 2016

Titan Pharmaceuticals Announces First Patients Treated With Probuphine(R) for Opioid Dependence

June 20, 2016

Titan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine(R) for Opioid Dependence

June 15, 2016

Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine(R)

June 13, 2016

Titan Pharmaceuticals Announces FDA Approval of Probuphine(R) for the Treatment of Opioid Dependence

May 26, 2016

  • « Previous
  • 1...
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • ...24
  • Next »
© 2022 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap